PANACEABIOPanacea Biotec Limited
Convert to ideaPharmaceuticals & Biotechnology · Biotechnology
The verdict combines business quality, price and timing. Sign in free to see it.
Sign in freeUp 1.8 this quarter.
Momentum from moving averages, Supertrend and RSI.
1 forensic issue found. Sign in to see which.
Valuation Metrics
Q2 FY2027Intrinsic value, Graham number and DCF against today's price
1 found · risk minor
Quality, growth, balance sheet and earnings quality behind the score
ⓘ Based on fundamental & forensic analysis. Always verify against official filings and consult a financial advisor.
Financial Metrics
Comparing Q2 FY2027 vs Q2 FY2026
| Quarter | Revenue | Net Profit | OPM | NPM | EPS | Int. Cover |
|---|---|---|---|---|---|---|
| Q2 FY2027 | ₹190 Cr | ₹12 Cr | 4.33% | 6.28% | ₹1.90 | 29.3x |
| Q1 FY2027 | ₹200 Cr | ₹2 Cr | -1.12% | 1.10% | ₹0.38 | 4.0x |
| Q4 FY2026 | ₹167 Cr | ₹-1 Cr | -3.18% | -0.60% | ₹0.08 | -0.0x |
| Q3 FY2026 | ₹165 Cr | ₹4 Cr | 1.99% | 2.35% | ₹0.65 | 4.5x |
| Q2 FY2026 | ₹141 Cr | ₹-14 Cr | -18.51% | -9.93% | ₹-2.27 | -8.0x |
| Q1 FY2026 | ₹167 Cr | ₹4 Cr | -5.74% | 2.38% | ₹0.66 | 8.6x |
Momentum score, 1-year chart, moving averages, support and resistance.
Turnaround stage, and how each measure moved over 3 years against the company's own range.
Order wins, capex, pledges, rating actions and every material filing.
Management guidance, Q&A highlights and whether they delivered what they said.
The earnings call read across investor dimensions.
Promoter, FII and mutual fund holding, and what changed this quarter.
Similar-size peers in Biotechnology
Compare with peers →Panacea Biotec Limited, a biotechnology company, engages in the research, development, manufacture, and marketing of vaccines, pharmaceutical formulations, nutraceuticals, and food and nutrition products in India and internationally. It operates through Vaccines and Pharmaceutical formulations & Nutrition segments. The company's product portfolio includes prescription products in various therapeutic areas, such as oncology, diabetes, gastro-intestinal care, nephrology, orthopedics, pain management, and fever; cold and cough; and betacoronavirus, SARS-CoV-2, typhoid conjugate, pneumococcal conjugate, tetravalent dengue, Mpox, and hepatitis A vaccines, etc. It also offers health supplement products; and paediatric nutrition products under the ChilRunFull, ChilRun 7+, and ChillRun No Sucrose brands. In addition, the company engages in the real estate business. It exports its products to approximately 50 countries. The company has collaboration agreements with the Russian Direct Investment Fund for producing Covid-19 vaccine, and Sputnik-V; and the Indian Council of Medical Research for clinical trials of DengiAll vaccine. Panacea Biotec Limited was incorporated in 1984 and is based in New Delhi, India.
Note: This comprehensive analysis combines technical data, fundamental data, and investment thesis. Always do your own research and consider your personal risk tolerance before investing.